BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23718539)

  • 1. Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains.
    Lee D; Kalff A; Low M; Gangatharan S; Ho P; Bajel A; Ritchie D; Grigg A; Spencer A
    Br J Haematol; 2013 Aug; 162(3):371-5. PubMed ID: 23718539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
    Jurczyszyn A; Grzasko N; Gozzetti A; Czepiel J; Cerase A; Hungria V; Crusoe E; Silva Dias AL; Vij R; Fiala MA; Caers J; Rasche L; Nooka AK; Lonial S; Vesole DH; Philip S; Gangatharan S; Druzd-Sitek A; Walewski J; Corso A; Cocito F; Vekemans MC; Atilla E; Beksac M; Leleu X; Davila J; Badros A; Aneja E; Abildgaard N; Kastritis E; Fantl D; Schutz N; Pika T; Butrym A; Olszewska-Szopa M; Usnarska-Zubkiewicz L; Usmani SZ; Nahi H; Chim CS; Shustik C; Madry K; Lentzsch S; Swiderska A; Helbig G; Guzicka-Kazimierczak R; Lendvai N; Waage A; Andersen KT; Murakami H; Zweegman S; Castillo JJ
    Am J Hematol; 2016 Jun; 91(6):575-80. PubMed ID: 26955792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia.
    Sanders KE; Ha CS; Cortes-Franco JE; Koller CA; Kantarjian HM; Cox JD
    Cancer; 2004 May; 100(10):2176-80. PubMed ID: 15139061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of central nervous system myeloma in the era of novel agents.
    Gangatharan SA; Carney DA; Prince HM; Wolf MM; Januszewicz EH; Ritchie DS; Harrison SJ
    Hematol Oncol; 2012 Dec; 30(4):170-4. PubMed ID: 22144117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment results and the prognosis in patients with localization of non-Hodgkins-lymphoma in the central nervous system].
    Paulus JA; Bos GM; Löwenberg B; Van Den Bent MJ
    Ned Tijdschr Geneeskd; 1998 Oct; 142(40):2196-200. PubMed ID: 9864481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of central nervous system myelomatosis with complex chromosome aberrations].
    Bang HI; Yoo JY; Kim KH; Park R; Shin JW; Choi TY; Lee SC; Park HS; Won JH
    Korean J Lab Med; 2010 Aug; 30(4):334-8. PubMed ID: 20805703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
    Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas.
    Schroers R; Baraniskin A; Heute C; Kuhnhenn J; Alekseyev A; Schmiegel W; Schlegel U; Pels HJ
    Eur J Haematol; 2010 Sep; 85(3):236-42. PubMed ID: 20528903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
    Abdallah AO; Atrash S; Shahid Z; Jameel M; Grazziutti M; Apewokin S; Kumar NS; Restrepo A; Waheed S; Van Rhee F; Heuck CJ; Johann D; Barlogie B; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):211-4. PubMed ID: 24373936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL13 and CXCL12 in central nervous system lymphoma patients.
    Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
    Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course and prognosis of non-secretory multiple myeloma.
    Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
    Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid.
    Arneth B; Birklein F
    Acta Neurol Scand; 2009 Jan; 119(1):39-44. PubMed ID: 18573131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
    Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
    Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased intrathecal immunoglobulin synthesis of both kappa and lambda types in patients with systemic lupus erythematosus and central nervous system involvement.
    Hirohata S; Miyamoto T
    J Rheumatol; 1986 Aug; 13(4):715-21. PubMed ID: 3095548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma invasion of the central nervous system.
    Marjanović S; Mijusković Z; Stamatović D; Madjaru L; Ralić T; Trimcev J; Stojanović J; Radović V
    Vojnosanit Pregl; 2012 Feb; 69(2):209-13. PubMed ID: 22500379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature.
    Selch MT; Shimizu KT; De Salles AF; Sutton C; Parker RG
    Am J Clin Oncol; 1994 Aug; 17(4):286-93. PubMed ID: 8048389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
    Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
    Katodritou E; Terpos E; Kastritis E; Delimpasis S; Symeonidis AS; Repousis P; Kyrtsonis MC; Vadikolia C; Michalis E; Polychronidou G; Michael M; Papadaki S; Papathanasiou M; Kokoviadou K; Kioumi A; Vlachaki E; Hadjiaggelidou C; Kouraklis A; Patsias I; Gavriatopoulou M; Kotsopoulou M; Verrou E; Gastari V; Christoulas D; Giannopoulou E; Pouli A; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
    Ann Hematol; 2015 Dec; 94(12):2033-42. PubMed ID: 26420061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system myelomatosis: review of the literature.
    Nieuwenhuizen L; Biesma DH
    Eur J Haematol; 2008 Jan; 80(1):1-9. PubMed ID: 17961180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.